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To the reader  
 
The project on following up and improving access to cancer care was launched and financed by the Minis-
try of Social Affairs and Health (STM) and carried out as a joint project with the National Institute for 
Health and Welfare (THL) and with the Cancer Society of Finland in 2015-2016. The objective of the pro-
ject was to create a national follow-up and reporting system regarding access to cancer care.  
 
THL was responsible for the project's coordination and practical implementation. Implementation work 
was carried out in cooperation with the Cancer Society of Finland.  
 
The objectives of the project were:  
1) to prepare a guide for following up on access to care; 
2) to develop a system for collecting data regarding access to care; and 
3) to develop a reporting system for national access to cancer care.  
 
Another objective of the 'Follow-up of access to cancer care' guide was to harmonise the recording practic-
es of cancer diagnoses and treatments.  This would allow reliable monitoring of cancer patients’ access to 
care, based on data recorded in the Hospital Discharge Register and reporting of access to care in Finland.  
The guide also specifies the appropriate time lines applicable in the follow-up of cancer care.  
 
This guide is intended for those managing cancer patients’ access to care, those in charge of recording ac-
cess to care data, and those recording such data in the patient information systems. It is also useful for those 
who make changes to patient information systems and sampling, and other parties using data on cancer 
patients’ access to care. Timely access to care is critical in the case of a number of cancers, in order to en-
sure a good clinical outcome. Efforts are also made to safeguard equal access to care for all citizens in situ-
ations where the patient is very concerned about the nature of the disease, even if the matter is not consid-
ered urgent in medical terms. 
 
The project was followed and quided by a steering group, which comprised specialists from all university 
hospitals, Hyvinkää hospital, and Vaasa central hospital. The steering group also included specialists from 
the Ministry of Social Affairs and Health, the Cancer Society of Finland, Finnish Cancer Registry, and 
National Supervisory Authority for Welfare and Health (Valvira). Other participating members included 
medical specialists involved in the treatment of various cancers. 
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Abstract 
Maarit Sillanpää, Liisa Pylkkänen and Pirjo Häkkinen (ed.). Follow-up of access to cancer care. National 
Institute for Health and Welfare (THL). Directions 4/2017. 45 pages. Helsinki 2017. 
ISBN 978-952-302-820-3 (online publication) 
The objective of the project was to create a national follow-up and reporting system on access to cancer 
care. The project involved the preparation of this guide, 'Follow-up of access to cancer care'. The defini-
tions given in this guide served as a basis for the follow-up system for access to cancer care. This system 
enables national reporting on follow-up results.  
Follow-up of access to cancer care will initially be conducted for 16 cancer types, which cover almost 75% 
of all new cancer cases reported each year (Finnish Cancer Registry
1
). In each cancer case, the follow-up
covers the entire care path from the arrival of the referral to specialised medical care, the first  appointment 
with a doctor (or telephone consultation or other similar arrangement) after the referral, placement on a 
waiting list, and the first cancer treatment. The dates are recorded to measure the time from the arrival of 
the referral to the first appointment with a doctor and the first treatment. Similarly, the time from placement 
on a waiting list to the first cancer treatment is measured. 
The first cancer treatment can be surgery, chemotherapy, radiotherapy, other therapy (such as local cancer 
therapy), active surveillance, and palliative care. These different treatment options can be monitored using 
diagnostic and procedure codes. The various types of cancer treatments taken into account in cancer care 
follow-up and reporting, and their produre codes, are listed in the guide. 
In addition, the guide specifies the recommended maximum waiting times for the various care paths for 
breast, prostate and colorectal cancers, and the different stages involved starting from placement of a pa-
tient on a waiting list. These three cancers were selected due to their prevalence (Finnish Cancer Registry
1
).
The recommended maximum waiting times are based on assessments by the steering group’s medical spe-
cialists. They take account of the biological characteristics of each cancer type and the medical data availa-
ble. In the future, the recommended maximum waiting times may be specified in more detail and their ap-
plication may be extended to other common cancer types.  
Key words: Diagnosis, cancer treatment, access to care, Hospital Discharge Register (Hilmo), procedure, 
follow-up, waiting time.   
1 http://www.cancer.fi/syoparekisteri/ 
National Institute for Health and Wel-
fare (THL) – Directions 4/2017 
5 
Follow-up of access to 
 cancer care 
Contents 
To the reader ................................................................................................................................................. 3 
Abstract .......................................................................................................................................................... 4 
1 Background information on the development of cancer care in Finland .............................................. 7 
2 Data collection starting points ................................................................................................................... 8 
2.1 The project to follow up and improve access to cancer care ............................................................... 8 
2.2 Legislation ......................................................................................................................................... 10 
2.3 Purpose of use .................................................................................................................................... 10 
3 Principles applied in the collection of data............................................................................................. 11 
3.1 Data collection is based on data in the Hospital Discharge Register ................................................. 11 
4 Follow-up of access to cancer care .......................................................................................................... 13 
4.1 Development needs regarding follow-up of access to cancer care in Finland ................................... 13 
4.2 Follow-up of access to cancer care in some other countries .............................................................. 13 
4.3 Principles for the follow-up of access to cancer care ......................................................................... 14 
4.3.1The essential definitions and follow-up times ............................................................................ 14 
4.3.2 Follow-up of breast cancer, prostate cancer and colorectal cancers .......................................... 18 
4.3.3 Other common cancers and their follow-up .............................................................................. 20 
4.4 Relevant data in the follow-up of access to cancer care .................................................................... 21 
4.4.1 Surgery ...................................................................................................................................... 21 
4.4.2 Chemotherapy ............................................................................................................................ 21 
4.4.3 Radiotherapy .............................................................................................................................. 21 
4.4.4 Other treatments ........................................................................................................................ 21 
4.5 Instructions for recording cancer treatment ....................................................................................... 22 
4.5.1 Instructions for recording diagnoses .......................................................................................... 22 
4.5.2 Instructions for recording cancer operations ............................................................................. 23 
4.5.3 Instructions for recording chemotherapies ................................................................................ 34 
4.5.4 Instructions for recording radiotherapy ..................................................................................... 39 
4.5.5 Instructions for recording other procedures ............................................................................... 43 
5 Submitting the data .................................................................................................................................. 44 
6 Reporting .................................................................................................................................................. 44 
References .................................................................................................................................................... 45 
National Institute for Health and Wel-
fare (THL) – Directions 4/2017 
7 
Follow-up of access to 
 cancer care 
1 Background information on the devel-
opment of cancer care in Finland 
In 2010, a working group appointed by the Ministry of Social Affairs and Health (STM) in 2009, issued 
recommendations on the development of cancer care in Finland.  Previous studies had shown that there was 
an unnecessarily long delay in access to cancer care (Working papers of the National Research and Devel-
opment Centre for Welfare and Health, STAKES, 33/2008).   
One of the action points included in the final report of the working group, ‘Development of cancer treat-
ment in 2010–2020’ (STM Reports 6/2010), involves specifying maximum waiting times for cancer diag-
nosis and treatment. To continue the work carried out by the STM working group, the National Institute for 
Health and Welfare (THL) appointed an oncology specialist group for 2013–2014. This group published its 
report ‘Development of cancer prevention, early detection  and rehabilitative support  2014–2025’ in May 
2014 (THL Directions 6/2014). In addition, a report by a working group preparing the establishment of a 
National Comprehensive Cancer Centre was published in May 2014 (STM reports and memorandums 
13/2014). Together, these reports provide a foundation for Finland’s cancer policy. The time requirements 
for access to cancer care were addressed in the first report only, which proposed the introduction of indica-
tive maximum waiting times. The ultimate goal of enhanced follow-up of access to cancer care is to im-
prove and accelerate early diagnoses and access to care, and thereby to contribute towards a more positive 
prognosis for cancers.  
With regard to urgent care, current legislation only contains provisions on emergency care. The maximum 
waiting times for access to non-urgent care specified in the current legislation are too long for cancer pa-
tients. THL’s follow up data on access to specialised medical care currently cover the waiting times speci-
fied in the Health Care Act (sections 51–53 of the Health Care Act). In 2015, STM appointed a working 
group to revise and harmonise the waiting times and criteria for access to care, and the criteria for non-
urgent and urgent care nationwide.  
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2 Data collection starting points 
2.1 The project to follow up and improve access to cancer care 
In late 2014, STM and THL launched a joint project to follow up and improve access to cancer care. For 
project implementation, THL partnered with the Cancer Society of Finland, whose representatives served 
as specialists in the project and participated in the coordination of cancer treatment expert resources re-
quired for the project. The project period was 15 November 2014 – 31 December 2015, but this was ex-
tended to 1 December 2016. 
The project comprised the following areas: 
 Preparation of a guide for the follow-up of access to cancer care
 Development of a system for collecting data on access to cancer care
 Development of a reporting system for national access to cancer care.
On 11 March 2015, the Director General of THL appointed a steering group for the follow-up and steering 
of the project. The chairperson of the steering group was Nea Malila, Director of the Finnish Cancer Regis-
try, and its vice chairperson was Timo Keistinen, Ministerial Counsellor for Medical Affairs, Ministry of 
Social Affairs and Health. The steering group included medical specialists from all university hospitals, 
Hyvinkää Hospital and Vaasa Central Hospital (Table 1). Specialists from Valvira, the Cancer Society of 
Finland and THL were also included in the steering group. 
Table 1. Members of the steering group for the project to follow up and improve access to cancer care 
Member Deputy member 
Petri Bono, HUCH/HUS 
Chief Medical Officer 
Mauri Kouri, HUCH Cancer Center/HUS 
Chief Medical Officer  
Antti Jekunen, University of Turku, Vaasa Central Hospital, Oncolo-
gy/TY/VSHP 
Chief Physician  
Heidi Bengts, Vaasa Central Hospital, Oncology/VSHP 
Head of Department 
Sirkku Jyrkkiö, TYKS, Operational Division of Surgery and Cancer 
Diseases/VSSHP 
Head of Division 
Outi Lahdenperä, TYKS/VSSHP 
Medical specialist 
Ulla Keränen, Hyvinkää Hospital, Department of Surgery /HUS 
Head of Division, Chief Medical Officer , Surgery  
(Member in 2015)  
Juhani Sand, TAYS/PSHP 
Head of Division, Chief Medical Officer 
Katariina Klintrup, OYS/PPSHP  
Department of Oncology and Hematology  
Deputy Chief Medical Officer, Head of Department   
Merja Korpela, OYS/PPSHP 
Department of Oncology and Hematology , 
Specialist in Oncology and Radiotherapy  
Tuula Lehtinen, TAYS/PSHP 
Chief Medical Officer, Head of the Department of Oncology 
Maarit Bärlund, TAYS/PSHP 
Assistant Chief Medical Officer  
Anna Lepistö, HYKS/HUS  
Head of Colorectal Surgery Department 
(Member in 2016) 
Kristiina Tyynelä-Korhonen, KYS/PSSHP 
Chief Medical Officer, The Chief of the Center of Oncology, Obstet-
rics and Gynekology  
Päivi Auvinen, KYS 
Chief Physician 
Aino Lepäntalo, HYKS/HUS 
Medical specialist 
2 Data collection starting points 
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Kirsi Liukkonen, Valvira 
Senior Officer, Legal Affairs   
Leena-Maija Vitie, Valvira 
Senior Officer, Legal Affairs 
Liisa Pylkkänen, the Cancer Society of Finland 
Chief Medical Officer 
Pirjo Häkkinen, THL 
Development  Manager 
Aleksi Yrttiaho, THL 
Development Manager 
Jaason Haapakoski, THL 
Senior Specialist 
Maarit Sillanpää, THL 
Project Manager 
Other specialists invited to participate in the preparation of this guide included Juho Lehto, Chief Physician 
(Palliative Care Unit, Department of Oncology, TAYS and the University of Tampere), and the Medical 
Specialists listed below, who were consulted on the surgical treatment of different cancers. 
Table 2.  Specialists in the treatment of different cancers 
Medical Specialist Cancer 
Peter Boström, TYKS/VSSHP 
Chief Medical Offiicer, Urology 
Bladder and urinary tract cancer 
Sakari Hietanen, TYKS/VSSHP 
Head of the Division  
Endometrial and ovarian cancer 
Sirkku Jyrkkiö, TYKS, Operational Division of Surgery and Cancer 
Diseases/VSSHP 
Head of division 
Lymphomas 
Petri Koivunen, OYS/PPSHP 
Chief Medical Officer  
Head and neck cancers 
Aki Laakso, HYKS/HUS 
Administrative Deputy  Chief Physician 
Brain and central nervous system cancers 
Marjut Leidenius, HYKS/HUS 
Head of Department 
Breast cancer 
Anna Lepistö, HYKS/HUS 
Head of Colorectal Surgery Department 
Colon and rectal cancer 
Mika Matikainen, HYKS/HUS 
Chief Medical Officer  
Prostate and testicular cancer 
Harry Nisén, HYKS/HUS 
Senior Physician 
Kidney cancer 
Juhani Sand, TAYS/PPSHP 
Head of Divison, Chief Medical Officer 
Pancreatic and stomach cancer 
Eero Sihvo, Central Finland Central Hospital/KSSHP 
Chief Medical Offiicer 
Lung and tracheal cancer 
Meri-Sisko Vuoristo, Pirkanmaa Cancer Society  
Chief Medical Officer  
Melanoma 
Abbreviations used for the hospitals: HUCH Helsinki University Central Hospital, KYS Kuopio University Hospital, OYS Oulu University 
Hospital, TAYS Tampere University Hospital and TYKS Turku University Central Hospital. TY University of Turku. 
Abbreviations used for the hospital districts: HUS Hospital district of Helsinki and Uusimaa; KSSHP Hospital district of Central Finland, 
PPSHP Hospital district of North Ostrobothnia, PSHP Hospital district of  Pirkanmaa, PSSHP Hospital district of North Savo, VSHP Hospi-
tal district of Vaasa, and VSSHP Hospital district of Southwest Finland. 
THL’s Senior IT System analysts Raimo Mahkonen and Satu Kerppilä also participated in the development 
of the follow-up and reporting of access to cancer care. 
2 Data collection starting points 
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2.2 Legislation 
The Act on the Statistical Service of the National Research and Development Centre for Welfare and 
Health (409/2001) provides the legal basis for the collection of data on access to cancer care. The collection 
of data on inpatient and outpatient health care (Hilmo data collection) is based on the Act (556/1989) and 
Decree (774/1989) on National Personal Records Kept under the Health Care System. Pursuant to Section 
11 of the Act on the National Institute for Health and Welfare (668/2008), these acts have been applied to 
THL’s activities since 1 January 2009. In addition, amendments to legislation being circulated for state-
ments with regard to the legislative proposals ‘Secure use of social welfare and health care data and certain 
related acts’ and ‘The organisation or social welfare and health care and certain related acts’ will, once they 
enter into force, affect the legal basis of data collection.  
2.3 Purpose of use 
The purposes for which the data on cancer diagnosis and access to care will be used: 
 To provide information on the follow-up, supervision and statistics regarding access to cancer care
 To provide information for research and decision-making
 To serve as a health care system performance indicator.
National Institute for Health and Wel-
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3 Principles applied in the collection of da-
ta  
This guide specifies the necessary time points, time intervals, concepts and procedures relevant to the fol-
low-up of cancer patients’ access to care. It also provides instructions for the recording of various cancer 
treatment procedures and diagnoses.    
The instructions for the collection of data on access to cancer care are intended for the following: 
 Those in charge of implementing access to cancer care
 Those in charge of supervision of access to cancer care
 Those in charge of consistent recording of data regarding access to care and of providing instruc-
tions to users
 Those entering access to care data in the patient information systems
 Those making changes in patient information systems and sampling
 Those utilising cancer patients’ access to care data.
THL is responsible for the maintenance and development of data content, classification, sampling and re-
porting related to access to cancer care. Similarly, working groups involved in access to specialised medical 
care can contribute their expertise to the specification and development work of cancer care. These working 
groups consist of representatives of the hospital districts, primary health care, specialised medical care, 
patient information system suppliers, THL, STM, Regional State Administrative Agencies and Valvira. In 
addition, the insights and policies of THL’s Hilmo expert group affect development and maintenance work 
related to the follow-up of cancer care, because the cancer care information is included in Hilmo data. An 
expert group or network will be appointed to oversee the improvement of access to cancer care and quality 
assurance. 
3.1 Data collection is based on data in the Hospital Discharge Register 
The Hospital Discharge Register (Hilmo) provides the foundation for the follow-up of access to cancer 
care. 
According to law, municipalities and joint municipal authorities, members of the public and some private 
health care service providers (inpatient care and day surgery), and health care and pharmacy personnel have 
an obligation to provide information to THL free of charge, confidentiality provisions notwithstanding. 
According to law, health care information will be recorded for each patient, alongside identifying personal 
information. Only information relevant to the health care units’ operations and allocation of activities will 
be recorded.  
THL’s Hilmo register provides information on different types of care episodes such as in-patient care, day 
surgery visits, outpatient visits and procedures performed during such visits. Information on radiotherapy 
and chemotherapy can also be obtained from Hilmo data, when the procedure codes are accurately recorded 
in the patient information systems. Hilmo data also contains the cancer diagnoses required for the follow-
up of access to cancer care, recorded according to the ICD-10 disease classification. In the future, these 
codes and diagnostic information can offer valuable information on the treatment of metastatic/recurrent 
cancer. Dates regarding referrals and placement on a waiting list can also be obtained from Hilmo. 
3 Principles applied in the collection of data 
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Key epidemiological data, such as data on new cancer cases and patient mortality, are obtained from the 
Finnish Cancer Registry
2
. Information regarding care systems and cancer prevention is available from 
THL, and from data and studies compiled by the Finnish Institute of Occupational Health (TTL)
3
 and the 
Radiation and Nuclear Safety Authority (STUK)
4
.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 http://www.cancer.fi/syoparekisteri/ 
3 https://www.ttl.fi/en/ 
4 http://www.stuk.fi/ 
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4 Follow-up of access to cancer care 
4.1 Development needs regarding follow-up of access to cancer care in Finland 
According to the recommendations of a working group appointed by the Ministry of Social Affairs and 
Health for the development of cancer treatment, demanding surgery, diagnosis and treatment requiring 
special expertise or expensive investments should be organised centrally. Some cancer treatments can be 
planned centrally but provided locally, closer to the patient’s residence. According to expert evaluations, 
primary health care will be increasingly involved in the follow-up and palliative care of cancer patients 
(STM Reports 6/2010). 
With this background information in mind, the working group made suggestions for the improvement of 
cancer care, in order to clearly define roles and responsibilities, and to set maximum waiting times for ac-
cess to cancer care. The maximum waiting time for patients with suspected cancer, from referral to first 
treatment (surgery, chemotherapy or radiotherapy), is 6 weeks.  For patients with cancers requiring urgent 
treatment, the waiting time must be shorter. Treatment should begin within a few days or within 2-3 weeks 
from the diagnosis at the latest. If cancer is suspected, the radiology report of the imaging test must be 
available within one week from the referral for such a test. If cancer is suspected, a tissue sample (surgical 
or needle biopsy) must be taken within one week from the arrival of a request for examination at the surgi-
cal unit or imaging unit. A pathologist’s report must be available within one week from the tissue biopsy, 
unless a cancer diagnosis requires the use of special diagnostic tests. Any adjuvant therapies after surgery 
(radiotherapy or chemotherapy) must commence no later than 4 weeks after surgery, unless a longer period 
is required for patient-related reasons (such as recovery from the surgical procedure). 
The working group for the development of cancer treatment proposed that the maximum waiting times 
specified above should, as a rule, also apply to the diagnostics and treatment of recurrent cancer. Treatment 
for difficult or severe cancer-related symptoms such as pain, impending paresis, or venous or other block-
ages, should be available without delay in all care units.  
4.2 Follow-up of access to cancer care in some other countries 
In other Nordic countries, there are varying practices for following up patients’ access to cancer care. In 
Denmark, recommendations have been issued for cancer-type specific times for different treatments (sur-
gery/chemotherapy/radiotherapy). The time from referral to first treatment is monitored as a rule. Adher-
ence to these recommended times is monitored in five regions in Denmark and for the entire country, quar-
tely and yearly. Furthermore, an annual analysis is prepared to indicate the percentage of patients that re-
ceived treatment within the recommended time
5
. In Denmark, the cancer treatment follow-up system covers
33 different types of cancers, including pediatric cancers as one entity.  
The follow-up model used in Norway is very similar to the one used in Denmark. There are recommended 
times for different cancer types, and they are very short 
6
.
5 http://sundhedsdatastyrelsen.dk/da/tal-og-analyser/analyser-og-rapporter/monitoreringer/kraeft 
6 https://helsedirektoratet.no/kreft 
4 Follow-up of access to cancer care 
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In Sweden, the time monitored covers the period from the preparation of a referral to the first treatment for 
bladder, kidney, colon, prostate and rectal cancers. For cancers of the head and neck and for lung cancers, 
the time span monitored is from referral to first treatment, for breast cancer from the first specialist ap-
pointment to treatment, and for melanoma from first specialist appointment to diagnosis. The medians of 
these time lines are monitored and reported annually for the different regions of Sweden, and for the entire 
country
 7
.
In England, the cancer treatment follow-up model is based on time recommendations, which apply to the 
treatment of all cancers. The general recommendations provide the following time lines: No more than two 
weeks from a GP’s urgent referral to first consultant appointment for a case of suspected cancer, and no 
more than 2 months from a GP’s urgent referral to treatment. In addition, the maximum time from a deci-
sion to treat to the first treatment is one month, from a referral by a national screening service to first treat-
ment 62 days, and to second or subsequent treatment 31 days. This data is reported monthly and annually
 8
.
4.3 Principles for the follow-up of access to cancer care 
The objective of conducting the follow-up of patients’ access to cancer care is to provide regional and pro-
vider-specific information on how long patients must wait before they receive treatment for their cancer. 
Follow-up focuses on the time from a specific cancer diagnosis to access to the first cancer treatment; this 
treatment may be surgery, chemotherapy, radiotherapy, other cancer treatment, active surveillance, or palli-
ative treatment (Figure 1). Treatment may be given for primary or recurrent/metastatic cancer. Surgical 
operations to be followed up for each type of cancer are listed in the section 4.5.2 ‘Recording cancer opera-
tions’. The treatment procedures to be followed up include surgical treatment, chemotherapy and radiother-
apy given at all stages of the cancer (primary/recurrent/metastatic). The key objective is to follow up on the 
first treatment. 
4.3.1 The essential definitions and follow-up times 
Definitions 
A referral is a document in which a social welfare and health care service provider submits a service re-
quest concerning a customer to another service provider.  
Received referral means the first referral for the health problem in question (Hilmo guidance). 
 Urgent referrals for the same health problem will not create a new event.
 Inter-organisational transfers between wards, specialties or departments do not require a new refer-
ral if the patient is being treated for the same health problem.
 An internal referral is required if a new health problem is being treated and responsibility for care
transfers to another specialty and department. An internal referral transfers responsibility for care
to another specialty or department within the same organisation.
 For patients requiring emergency care or patients with no referral, the patient’s arrival date is rec-
orded as the referral arrival date.
7 http://www.socialstyrelsen.se/sjukdomar/cancer 
8 http://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/ 
4 Follow-up of access to cancer care 
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Referral arrival date is the date on which the referral was first received by an institution or specialised 
medical care unit for the assessment of a health problem (Hilmo guidance). 
First appointment with a doctor at the care unit in question is the patient’s first contact with the doctor 
after the arrival of the referral with regard to the disease/health problem in question.  
 This first contact may be a personal visit to a doctor, or a telephone consultation or similar, if it re-
places the first visit and is a personal consultation for which an appointment was made beforehand.
Date of placement on waiting list is the date on which a patient is placed on a waiting list to wait for inpa-
tient care, day surgery or outpatient treatment, operation or procedure. Patients should be placed on a wait-
ing list on the same day as the doctor makes a decision to start treatment (Hilmo guidance). 
Adjuvant therapy refers to treatment given soon after the local treatment of the tumour (usually an opera-
tion, sometimes radiotherapy). Adjuvant therapy is provided to destroy any cancer cells that cannot be 
eliminated using surgery or radiotherapy. The patient may be given only one adjuvant therapy, or several 
therapies either in succession or simultaneously. 
 Neoadjuvant therapy for cancer is provided before the operation or radiotherapy.
Active surveillance of a diagnosed cancer is recorded if the doctor estimates that treatment to cure cancer 
with surgery, radiotherapy or chemotherapy is not necessary but, instead, the patient’s condition can be 
regularly monitored. Treatment for cancer will be started if the cancer progresses or becomes more poorly 
differentiated.  
 Active surveillance of a diagnosed cancer may be a suitable approach for well differentiated, local
(low risk of progression) prostate cancer, small and well differentiated kidney cancers, and low-
grade malignant lymphoma with slow progression. This will help to avoid the unnecessary side ef-
fects of cancer treatment.
 Active surveillance of a diagnosed cancer is recorded when a patient’s cancer is not initially treat-
ed, only monitored for potential progression.  This is not recorded at other stages of the chain of
care.
 Procedure code XZZ00 is used for the active surveillance of a diagnosed cancer. This procedure
code will be included in the THL Classification of Procedures in Medicine
 9
 as of the beginning of
2017.
9 www.thl.fi/codeservice 
For example, the following would be recorded for the active monitoring of a patient with prostate can-
cer: 
 Diagnosis: prostate cancer C61
 Procedure: Active surveillance of a diagnosed cancer XZZ00
4 Follow-up of access to cancer care 
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Palliative, or symptomatic cancer care refers to the active comprehensive treatment of a cancer patient 
with the objective of alleviating the physical, psychological, social and mental suffering caused by the dis-
ease. As the disease advances, the need for palliative care usually increases. When treatment to slow down 
the progression of the disease is no longer effective or not in the patient’s best interests due to severe side 
effects, palliative care will be provided. Instead of attempting to slow down the progression of cancer, the 
focus is on alleviating the symptoms and maintaining the patient’s quality of life.  
 The doctor will record palliative care Z51.5 as the secondary diagnosis, and planning of interven-
tion or health care consultation WZC00 as the procedure code.  
 
 
 
 
 
 
 
 
Waiting times to be followed up  
 
The dates to be observed with regard to access to cancer care and treatment are the arrival of the referral, 
the first appointment with a doctor, placement on a waiting list, and the first cancer treatment (Figure 1). 
 
First cancer treatment is the treatment provided soonest after the arrival of the referral or placement on a 
waiting list. A cancer patient’s treatment options include surgery, chemotherapy, radiotherapy, or other 
treatment (various local treatments). Other alternatives include active surveillance of the cancer and symp-
tomatic, or palliative care. These procedures used for the treatment of different types of cancers are deter-
mined on the basis of the THL Classification of Procedures in Medicine and THL Classification of Diseas-
es ICD-10
10
: 
 Cancer-specific operations (tables 4–7) 
 Chemotherapy: procedure codes  beginning with WB−WE (tables 8−10) 
 Radiotherapy: procedure codes  beginning with HA0, WA0, WF0, XX7, AX099 and QX099 (table 
11) 
 Other cancer treatment: Local treatment of a tumour or abnormal tissue (table 12) 
 Active surveillance of a diagnosed cancer: XZZ00 procedure code will be included in the THL 
classification of Procedures in Medicine as of the beginning of 2017). 
 Palliative care of cancer: Z51.5. 
 
 
 
 
 
 
 
 
 
 
 
 
10 www.thl.fi/codeservice  
 
 
 
 
For example, the following would be recorded for a lung cancer patient’s palliative care: 
 Primary  diagnosis: lung cancer, e.g. C34.32 (Malignant neoplasm of lower lobe, left bron-
chus or lung; adenocarcinoma)  
 Secondary diagnosis: palliative cancer care Z51.5 
 Planning of intervention or health care consultation WZC00 during an appointment    
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Figure 1. The time points and time intervals relevant to the follow-up of cancer patients’ access to care 
1. total
waiting time
first cancer treatment, date
• Cancer-spesific operations
• Chemotherapy: procedure codes beginning
with WBWE
• Radiotherapy: procedure codes beginning
with HA0, WA0, WF0 and XX7, also AX099
and QX099
• Other cancer treatment: local treatment of
a tumour or abnormal tissue
• Active surveillance of a diagnosed cancer
XZZ00
• Palliative care of cancer Z51.5
arrival of the referral, date
3. 
placement in a waiting list, date
first appointment with a doctor, date
2. 
Time intervals are measured on the basis of the following time points: arrival of the referral, first appoint-
ment with a doctor, placement on a waiting list, and the first cancer treatment.  
1 Arrival of the referral – First cancer treatment  
This is the waiting time in full days from the arrival of the referral to the first cancer treatment. 
2 Arrival of the referral – First appointment with a doctor 
 This is the waiting time in full days from the arrival of the referral to the first appointment with a doctor. 
3 Placement on a waiting list – First cancer treatment 
This is the waiting time in full days from the placement on a waiting list to first treatment. 
The cancer treatment procedures may be recorded under primary or secondary procedures (THL – Classifi-
cation of Procedures in Medicine 
11
).
11 www.thl.fi/codeservice 
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4.3.2 Follow-up of breast cancer, prostate cancer and colorectal cancers 
 
The recommended maximum waiting times for access to cancer care for the following cancers 
 Invasive breast cancer and intraductal breast cancer (diagnoses beginning with C50 and D05.1) 
(Figure 2) 
 Prostate cancer (diagnoses beginning with C61) (Figure 3) 
 Colon and rectal cancer (diagnoses beginning with C18-20) (Figures 4 and 5)  
 
The recommended maximum waiting times for alternative care pathways are presented from the date of 
placement on a waiting list. The recommended maximum waiting times are based on assessments by the 
steering group’s medical specialists. They take account of the biological characteristics of each cancer type 
and the medical data available.    
Figure 2. The recommended maximum waiting times for breast cancer patients from placement on a wait-
ing list to first treatment and postoperative adjuvant therapies 
Placement on a waiting list first treatment adjuvant therapy/seceond treatment
Breast cancer
C50 and D05.1
Operation
Radiotherapy
Chemotherapy
4 weeks
6 weeks
Operation
Radiotherapy
Chemotherapy
Chemotherapy
6 weeks4 weeks
4 weeks
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Figure 3. The recommended maximum waiting times for prostate cancer patients from placement on a 
waiting list to first treatment and adjuvant radiotherapy 
placement on a waiting list  first treatment adjuvant therapy
Prostate cancer
C61
Operation
Radiotherapy6 weeks
Chemotherapy for 
localized cancer: 
procedure codes
begining with WB-WC 
Radiotherapy
Active surveillance
Radiotherapy3 
months
Chemotherapy for 
metastatic cancer: 
procedure codes
beginning with WD 
4 weeks
3 
months
Figure 4. The recommended maximum waiting times for colon cancer patients 
Colon cancer
C18-19
Operation Chemotherapy
3 weeks
placement on a waiting list      first treatment   adjuvant therapy
Chemotherapy
6 weeks
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Figure 5. The recommended maximum waiting times for rectal cancer patients 
Rectal cancer
C20
Operation
3 weeks
placement on a               first treatment operation adjuvant therapy
waiting list
Short radio-
therapy: 5 x 5 Gy
Operation
Chemotherapy
8 weeks
Chemotherapy
6 weeks
Chemotherapy
6 weeks
Long radio-
therapy: 45-54 Gy
5 days
 
 
4.3.3 Other common cancers and their follow-up 
 
With regard to other cancers, the most common cancers and patients’ access to care are followed up until 
the first treatment, and reported using indicators as a median time to treatment. Table 3 contains a list of 
other cancers being followed up, with their THL Classification of Diseases ICD-10 compliant codes. Some 
less common cancers were also included which require urgent care (e.g. testicular cancer). In the future, 
follow up may be extended also to other cancers. 
Table 3. Other cancers included in the follow-up of access to care and their ICD-10 codes 
Cancer ICD-10 codes 
Head and neck cancers C00-14 and C30-32 
Stomach cancer C16 
Pancreatic cancer C25 
Lung and tracheal cancer C33-34 
Melanoma C43 
Endometrial cancer C54 
Ovarian cancer C56, C57.0-8 
Testicular cancer C62 
Kidney cancer C64 
Bladder and urinary tract cancer C65-68 
Brain and central nervous system can-
cers 
C70-72+C75.1-3 
Lymphomas C81-85 
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4.4 Relevant data in the follow-up of access to cancer care 
4.4.1 Surgery 
Relevant data on cancer operations includes the patient’s first actual cancer operation to remove local, re-
current or metastatic cancer. These operations do not include exploratory surgery, surgical opening of an 
area or a biopsy, which are included in cancer diagnostics. Similarly, corrective procedures or operations 
performed to deal with complications are not included in the follow-up of access to cancer care, with the 
exception of exploratory surgery conducted with the intention to treat metastatic cancer (such as pancreatic 
cancer) but which remains an exploratory surgery.  Similarly, palliative surgical procedures (such as surgi-
cal treatment of a bowel obstruction caused by intestine cancer) are considered procedures to be followed 
up (tables 4–7). 
4.4.2 Chemotherapy 
The procedure codes beginning with WB, WC, WD and WE in the THL Classification of Procedures in 
Medicine signify chemotherapy. Codes beginning with WB cover various drug therapies for a local primary 
tumour: cytotoxic drugs, immunomodulators, hormone therapies, antibody therapies, enzyme inhibitor 
therapies and other drug therapies to fight cancer. The procedure code also includes a description of the 
level of treatment: simple, demanding or very demanding. The procedure codes also help to describe 
whether the treatment was given as an adjuvant therapy, or before or after surgery or radiotherapy (neoad-
juvant therapy).  
The procedure codes beginning with WC refer to drug therapies for locally recurrent tumours or individual 
metastasis. They usually cover the same treatment options as those listed for primary tumours. The proce-
dure codes beginning with WD refer to drug therapies for metastatic cancer. The procedure codes begin-
ning with WE refer to preventive cancer treatment. 
4.4.3 Radiotherapy 
The procedure codes for radiotherapy beginning with WF0 refer to local radiotherapy. They also describe 
the stage of the patient’s treatment during which the therapy is given, and whether treatment is given for a 
primary tumour or metastatic cancer. The procedure codes beginning with WA refer to radiation therapy 
given on large areas of skin or body. There are also procedure codes beginning with HA0, which refer to 
radiation therapy given to the chest area, and procedure code AX099 for the central nervous system and 
QX099 for the skin. The procedure codes for radioisotope therapies begin with XX7. 
4.4.4 Other treatments 
Other types of cancer treatment subject to follow-up include stem cell transplantation procedure codes be-
ginning with WW_) and local treatments of tumours or abnormal tissue. 
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4.5 Instructions for recording cancer treatment 
 
The THL Classification of diseases ICD-10
12
 is used for recording the diagnoses of cancer patients, while 
the THL Classification of Procedures in Medicine
13
 is used for recording operations performed and chemo-
therapies, radiotherapies and other treatments given during inpatient stays and visits. 
4.5.1 Instructions for recording diagnoses 
 
The objective of the guide for structured recording in the health care sector (How to record the main record 
structures in electronic patient records, Part I, Version 2015) is to describe the recording practices and use 
of nationwide harmonised and structured patient data from the perspective of the person recording or using 
the data. The guide has been updated to match the situation in 2017–2018. The guide for structured record-
ing practices provides general instructions on how to record the reason for visit, reason for treatment and 
diagnoses.   
 
Instructions for recording diagnoses are also provided in a Finnish guide for recording diseases (THL 
Guide 17/2012) and in the THL Classification of Diseases ICD-10. The instructions of the Hilmo guide 
(THL Directions 11/2016) on recording diagnoses are also consistent with those provided in the guide for 
structured recording practices and the Finnish guide for recording diseases referred to above.  
 
Principal diagnosis or reason for care period or visit 
The guide for structured recording provides the following instructions: ‘Primary and secondary diagnoses 
are attributes used in the patient record to describe the significance of the recorded diagnosis in connec-
tion with each visit or inpatient stay. Primary diagnosis refers to the diagnosis that is the main reason for 
the patient’s treatment in the given care situation. Secondary diagnoses refer to other diagnoses that are of 
lesser importance but which nevertheless affect the examination, treatment, prognosis or health of the pa-
tient. 
 
Information indicating the principal nature of the diagnosis or reason for visit is recorded in accordance 
with the Principal diagnosis classes as primary and secondary. A primary diagnosis must be specified by 
the end of the inpatient stay or appointment at the latest. The health problem or disease that was the main 
reason for the visit or inpatient stay in question is recorded as the primary diagnosis. Only one primary 
diagnosis can be recorded for each appointment or inpatient stay.’ 
 
Recording diagnoses in cancer care 
 
When a patient is treated for cancer and the cancer has metastasised, both the primary and metastatic cancer 
are recorded, with their specific THL Classifiacation of Diseases ICD-10 codes. 
 
The cancer diagnoses refer only to primary cancers and do not provide any information on metastasis. The 
THL Classifiacation of Diseases ICD-10 contains separate diagnostic codes for metastasis (C77-79). These 
indicate the location of the metastasis but not its origin. 
 
How to record long-term cancer diagnoses 
 
Cancer diagnoses are recorded as long-term diagnoses. Existing conditions such as prostate cancer should 
be accounted for with respect to the patient’s potential other diseases. 
 
Similarly, palliative treatment of cancer (Z51.5) is also recorded as a long-term diagnosis. 
12 www.thl.fi/codeservice 
13 www.thl.fi/codeservice 
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Permanence of the diagnosis or reason for visit 
The guide for structured recording provides the following instructions: ‘Permanence refers to the time di-
mension of the diagnosis in the patient’s care. Permanence has to do with whether or not the diagnosis 
results in a long-term need for treatment, or whether it will affect the treatment provided for future health 
problems or other diseases. If relevant in terms of treatment, long-term diagnoses will also be recorded as 
diagnoses for the visit or inpatient stay. 
The permanence of the diagnosis can, where necessary, be described using the Permanence classes. A 
diagnosis can be made for a fixed term or on a permanent basis. 
A permanent diagnosis is made for the longer term and may have special relevance to the patient’s health, 
well-being and treatment, even after the disease or health problem has cleared up. Long-term diagnoses 
are often relevant to most contacts with patients, even if they were not the direct reason for seeking treat-
ment, and are therefore often recorded as secondary diagnoses for visits and inpatient stays. Long-term 
diagnoses are listed in a summary of diagnoses provided by the Information Management Service, and 
remain listed until recorded as having ended.’ 
4.5.2 Instructions for recording cancer operations 
As noted above in section 4.4.1, relevant data on cancer operations includes the patient’s first actual cancer 
operation to remove local, recurrent and metastatic cancer. The purpose is to report the first treatment giv-
en, which in the case of advanced cancer can also mean palliative or exploratory surgery. 
Lymph node removal operations are considered primary cancer treatment subject to a follow-up, except in 
the case of lymphomas. In lymphoma patients, lymph node removals are considered diagnostic procedures 
and are not therefore included as operations to be followed up (table 7).  
With regard to cancers subject to follow-up for access to care, operations are grouped as follows: breast 
cancer operations in table 4, prostate cancer operations in table 5, colorectal cancer operations in table 6, 
and other cancer operations (cancer of the head and neck area, stomach, pancreas, lungs and trachea; mel-
onoma, corpus uteri, ovaries, testicles, kidneys, bladder and urinary tract, brain and central nervous system, 
and lymphomas) in table 7.  
Surgical treatment of breast cancer 
Surgical treatment of breast cancer is planned in consultation with the patient, taking account of the size of 
the tumour, the size of the patient’s breasts, and any pre-existing conditions the patient may have. A breast-
conserving operation should always be performed upon the patient’s request, unless there are contraindica-
tions. If a total mastectomy is required, the removed breast can be reconstructed either after the cancer 
operations, or after the adjuvant therapies have been completed. Reconstructive surgery is a major opera-
tion that often involves complications. That is why the patient must be in relatively good physical condi-
tion, motivated and well-informed.  
If an axillary metastasis has been diagnosed before the operation, an axillary lymph node evacuation will be 
performed. If no axillary metastasis has been diagnosed, a sentinel lymph node biopsy is generally per-
formed. The findings of this biopsy determine whether axillary lymph node evacuation, radiotherapy, or 
both are required, or whether monitoring will suffice.  
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If the breast cancer (either the primary tumour or the lymph node metastases) has spread locally, the first 
treatment given is drug therapy (neoadjuvant therapy). The operation performed following this therapy 
usually involves removing the breast and the axillary lymph nodes. 
 
The Finnish Breast Cancer Group has issued recommendations concerning breast cancer diagnosis and 
treatment, which are available on the organisation’s website
14
. 
 
Procedures beginning with HAD (corrective procedures) are not subject to surgical breast cancer treatment 
follow-up, with the exception of early-stage HAD30, which may be used as a surgery code in some hospi-
tals, if breast reduction surgical technique is used to perform the cancer operation. In the future, these types 
of operations will be recorded with the procedure code HAB50.   
 
Table 4. Surgical procedures subject to breast cancer treatment follow-up 
ICD-10 codes for breast cancer beginning with C50 and D05.1 
 Name of the group Code Procedure 
HAB Partial excision of mammary 
gland 
HAB30 Excision of mamilla or areola 
  HAB40 Wedge excision of mammary gland 
 
  HAB50 Partial excision of mammary gland with reconstructive opera-
tion Includes: Oncoplastic resection 
  HAB99 Other partial excision of mammary gland 
HAC Mastectomy HAC10 Subcutaneous mastectomy with preservation of mamilla 
  HAC15 Subcutaneous mastectomy with excision of mamilla 
 
  HAC20 Total mastectomy 
 
  HAC25 Radical mastectomy 
  HAC30 Excision of supernumerary mammary gland or mamilla 
  HAC99 Other mastectomy 
HAD Plastic operations on breast HAD30 Reduction mammoplasty with transposition of areola* 
HAF Operations for local recur-
rence of breast cancer 
HAF00 Excision of local recurrence of breast cancer 
  HAF10 Repair after excision of local recurrence of breast cancer 
using graft or flap 
PJA Exploration of lymph nodes PJA12 Sentinel node biopsy 
PJD Excision and block dissection 
of lymph nodes 
PJD42 Excision of axillary lymph nodes 
  PJD52 Block dissection of axillary lymph nodes 
* This code may be used in some hospitals if breast reduction surgical technique is used to perform the 
cancer operation. 
 
 
 
 
 
 
 
14 http://rintasyoparyhma.yhdistysavain.fi/hoitosuositus/
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Surgical treatment of prostate cancer 
Treatments aimed at curing local (T2) or locally advanced (T3N0M0) prostate cancer include radical sur-
gery or radiotherapy. The most common surgical procedure for curing prostate cancer is a radical prostatec-
tomy, which means removal of the prostate and the prostatic capsule. There are different types of radical 
prostatectomy: open (KEC00), minimally invasive laparoscopic (KEC01), or robot-assisted laparoscopic 
(KEC01, ZXC96) prostatectomy, the last-mentioned currently being the most common type of radical sur-
gery. The techniques used to perform open radical prostatectomy are retropubic (KEC00), perineal 
(KEC10) and transcoccygeal (KEC20) prostatectomy, the first one being clearly the most common. 
In local prostate cancer, the goal of radical prostatectomy is to remove the prostate and the prostatic cap-
sule, to remove all cancer tissue and thereby to cure the patient, and to minimise the harmful side effects of 
the operation in terms of postoperative morbidity, incontinence and sexual dysfunction. A radical prostatec-
tomy usually involves removing the seminal vesicles attached to the prostate. In the case of medium or 
high-risk patients, the procedure includes extended lymph node dissection around the iliac arteries (PJD64). 
For low-risk patients, because the probability of lymph node metastasis is small, no lymph node removal is 
generally required.  
In certain, special cases, second-line salvage treatment may include a radical prostatectomy, if the cancer 
recurs locally after radical radiotherapy. However, the risks of complications are significantly higher than 
in an operation performed as first-line treatment. 
The first-line treatment for metastatic prostate cancer is hormone therapy, which may involve a chemical 
castration with LHRH analogues or antagonists, or surgical castration which involves removing both testi-
cles (KFC10). Orchiectomy, or removal of the testicles, may involve total removal by cutting the funicles, 
or a subcapsular orchiectomy which involves saving the tunica albuginea and only removing the intracap-
sular testicular tissue. 
The recommendations for the diagnostics and treatment of prostate cancer prepared and updated by the 
Current Care Guidelines working group on prostate cancer are available on the Current Care Guidelines 
website 
15
.
Table 5. Surgical procedures subject to prostate cancer treatment follow-up 
ICD-10 codes for prostate cancer beginning with C61 
Name of the group Code Procedure 
KEC Total excision of prostate and 
seminal vesicles 
KEC00 Retropubic radical prostatectomy 
KEC01 Percutaneous endoscopic radical prostatectomy 
KEC10 Perineal radical prostatectomy 
KEC20 Transsacral radical prostatectomy 
KEC30 Removal of seminal vesicle 
KFC Total excision of testis and 
epididymis 
KFC10 Bilateral orchiectomy 
PJD Excision and block dissection 
of lymph nodes 
PJD44 Excision of iliac lymph nodes 
PJD54 Block dissection of iliac lymph nodes 
PJD64 Laparoscopic dissection of iliac lymph nodes 
15 http://www.kaypahoito.fi/web/english/home
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Surgical treatment of colorectal cancers  
 
The most common, first surgical treatment of colorectal cancer is the removal of the tumour. In colon can-
cer, surgery most typically involves a right and left hemicolectomy, depending on the location of the can-
cer. Sometimes a total colectomy may be required, after which the small intestine is connected to the rec-
tum. This procedure may be necessary if the patient has multiple tumours in the colon, or is genetically 
predisposed to colon tumours. 
 
The most common surgical treatments for rectal cancer are an anterior resection and abdominoperineal 
excision. An anterior resection involves removing the rectum and the lymph nodes in this part of the bowel, 
and joining the remaining parts of the colon and the rectum. In this type of operation, a temporary stoma 
may be required to protect the anastomosis. If the rectal cancer is located very low in the rectum, the anus 
will have to be removed. An abdominoperineal excision involves removing the rectum, the sphincter mus-
cles around the anus and, in locally advanced T3-T4 tumours, the pelvic diaphragm. The patient will have a 
permanent colostomy. When rectal cancer is associated with polyposis, a proctocolectomy is typically per-
formed to remove the entire colon and rectum. Sometimes the procedure may involve the construction of an 
ileal reservoir which is connected to the anus (ileoanal anastomosis), or, alternatively, a permanent ileosto-
my. 
 
If the patient needs preoperative radiotherapy for the rectal cancer but the tumour is blocking the bowel, a 
loop transverse colostomy is performed before radiotherapy to ensure that the patient can eat and have 
bowel movements during radiotherapy. A stoma also helps to alleviate the patient’s symptoms in a situation 
where the disease has advanced locally to the point that surgical removal of the tumour is no longer an 
option. 
 
Table 6. Surgical procedures subject to colorectal cancer treatment follow-up 
ICD-10 codes for colorectal cancers beginning with C18-20 
 Name of the group Code Procedure 
JAH Opening of peritoneal cavity 
JAH00 Laparotomy 
JFA Local operations on intestine 
JFA68 Endoscopic insertion of prosthetic tube into colon 
  
JFA83 Excision of lesion of colon 
  
JFA84 Laparoscopic excision of lesion of colon 
  
JFA96 Other local operation on intestine 
  
JFA97 Other laparoscopic local operation on intestine 
  
JFA98 Other transluminal endoscopic local operation on intestine 
JFB Partial excision of intestine 
JFB20 Ileocaecal resection 
  
JFB21 Laparoscopic ileocaecal resection 
  
JFB30 Right hemicolectomy 
  
JFB31 Laparoscopic right hemicolectomy 
  
JFB33 Other resection comprising small intestine and colon 
  
JFB40 Resection of transverse colon 
  
JFB41 Laparoscopic resection of transverse colon 
  
JFB43 Left hemicolectomy 
  
JFB44 Laparoscopic left hemicolectomy 
  
JFB46 Resection of sigmoid colon 
  
JFB47 Laparoscopic resection of sigmoid colon 
  
JFB50 Other resection of colon 
  
JFB51 Other laparoscopic resection of colon 
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JFB53 Resection of sigmoid colon with partial proctectomy 
JFB54 
Laparoscopic resection of sigmoid colon with partial 
proctectomy 
JFB60 Resection of sigmoid colon with end colostomy 
JFB61 
Laparoscopic resection of sigmoid colon with end colos-
tomy and closure of distal stump 
JFB63 
Other resection of colon with proximal colostomy and 
closure of distal stump 
JFB64 
Other laparoscopic resection of colon with proximal colos-
tomy and closure of distal stump 
JFB96 Other partial excision of intestine 
JFB97 Other laparoscopic partial excision of intestine 
JFC Anastomosis of intestine 
JFC10 Ileotransversostomy 
JFC11 Laparoscopic ileotransversostomy 
JFC20 Other enterocolostomy 
JFC21 Other laparoscopic enterocolostomy 
JFC30 Colo-colostomy 
JFC31 Laparoscopic colo-colostomy 
JFC40 Ileorectostomy 
JFC41 Laparoscopic ileorectostomy 
JFC50 Colorectostomy 
JFC51 Laparoscopic colorectostomy 
JFF Exteriorisation of intestine and 
creation of intestinal stomas 
JFF10 Loop enterostomy 
JFF13 Terminal enterostomy 
JFF11 Laparoscopic loop enterostomy 
JFF23 Transversostomy 
JFF26 Sigmoidostomy 
JFF27 Laparoscopic sigmoidostomy 
JFF30 Other colostomy 
JFF31 Other laparoscopic colostomy 
JFH Total colectomy 
JFH00 Total colectomy and ileorectal anastomosis 
JFH01 Laparoscopic colectomy with ileorectal anastomosis 
JFH10 Total colectomy and ileostomy 
JFH11 Laparoscopic colectomy 
JFH20 Proctocolectomy and ileostomy 
JFH30 
Total colectomy, mucosal proctectomy and ileoanal anas-
tomosis without ileostomy 
JFH31 
Laparoscopic total colectomy, mucosal proctectomy and 
ileoanal anastomosis without ileostomy 
JFH33 
Total colectomy, mucosal proctectomy, ileoanal anasto-
mosis and ileostomy 
JFH40 Proctocolectomy and continent ileostomy 
JFH96 Other total colectomy 
JGA Proctotomy and local operations 
on rectum 
JGA58 Endoscopic insertion of prosthetic tube into rectum 
JGA73 Transanal excision of lesion of rectum 
JGB Excision of rectum 
JGB03 Partial proctectomy with partial excision of mesorectum 
JGB04 
Laparoscopic partial proctectomy with partial excision of 
mesorectum  
JGB06 Partial proctectomy with total excision of mesorectum 
JGB07 Laparoscopic partial proctectomy with total excision of 
mesorectum  
4 Follow-up of access to cancer care 
 
National Institute for Health and Wel-
fare (THL) – Directions 4/2017 
28 
Follow-up of access to 
 cancer care  
 
 
  
JGB10 Partial proctectomy and end colostomy 
  
JGB11 Laparoscopic partial proctectomy and end colostomy 
  
JGB20 Partial rectosigmoidectomy and abdominoperineal pull-
through anastomosis 
  
JGB30 Abdominoperineal excision of rectum 
  
JGB31 Laparoscopic and perineal excision of rectum 
  
JGB36 Wide excision of rectum 
  
JGB37 Laparoscopic wide excision of rectum 
 
 
Surgical treatment of other cancers subject to follow-up  
 
Surgical treatment procedures of other cancers subject to  follow-up − cancer of the head and neck area, 
stomach, pancreas, lungs and trachea; melonoma, corpus uteri, ovaries, testicles, kidneys, bladder and uri-
nary tract, brain and central nervous system, and lymphomas – are listed in table 7. 
 
Table 7. Surgical procedures of other cancers subject to follow-up 
ICD-10 codes for cancers of the head and neck area beginning with C00-C14 and C30-C32 
 Name of the group Code Procedure 
  
DJW00 Removal of local lesion of nasal septum 
  
DMB10 Radical maxillary antrotomy 
  
DMB30 Transmaxillary excision of lesion of maxillary antrum 
  
DMB40 
Excision of lesion of maxillary antrum trough lateral rhi-
notomy 
  
DMW99 Other operation on maxillary antrum 
  
DNB30 Excision of lesion of ethmoidal sinus 
  
DNW99 Other operation on ethmoidal sinus and bone 
  
DPB10 Partial excision of sphenoidal sinus 
  
DQB10 Endoscopic excision of lesion of larynx 
  
DQB20 Partial excision of larynx 
  
DQB30 Laryngectomy 
  
DQB60 Aryotenoidectomy 
  
DQB70 Total excision of vocal cord 
EAA Incision and excision of lip 
EAA10 Excision of lesion of lip 
  
EAA20 Partial excision of upper lip 
  
EAA30 Partial excision of lower lip 
ECA Incision, biopsy and excision of 
gingiva and alveolus 
ECA30 Excision of lesion of gingiva 
  
ECA35 Complicated excision of lesion of gingiva 
EDB Excision of mandible 
EDB00 Partial excision of mandible 
  
EDB10 Mandibulectomy 
  
EDB20 Hemimandibulectomy 
  
EDB99 Other excision on mandible 
EDW Other operations on mandible 
EDW99 Other operation on mandible 
EEB Excision of maxilla 
EEB00 Partial excision of maxilla 
  
EEB10 Maxillectomy 
  
EEB20 Hemimaxillectomy 
  
EEB99 Other excision of maxilla 
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EHB Excision of palate 
EHB00 Excision of lesion of palate 
EHW Other operations on palate 
EHW99 Other operation on palate 
EJB Excision of tongue and floor of 
mouth EJB10 Excision of lesion of apex or body of tongue 
EJB20 Excision of lesion of base of tongue 
EJB30 Excision of lesion of floor of mouth 
EJB40 Hemiglossectomy 
EJB50 Total glossectomy 
EJB60 Partial excision of floor of mouth 
EJB99 Other excision on tongue and floor of mouth 
EJW Other operations on tongue and 
floor of mouth 
EJW99 Other operation on tongue or floor of mouth 
EKB Excision of cheek 
EKB00 Excision of lesion of cheek 
EKW99 Other operation on cheek 
ELB Excision of salivary gland 
ELB00 Excision or exploration of lesion of salivary gland 
ELB30 Excision of submandibular gland 
ELB40 Partial parotidectomy 
ELB50 Total parotidectomy 
EMB Excision of tonsils and ade-
noids EMB00 Excision of lesion of tonsil or adenoids 
ENB Excision of pharynx and adja-
cent structures 
ENB00 Excision or exploration of lesion of pharynx 
ENB20 Pharyngectomy 
ENB30 Laryngopharyngectomy 
ENB99 Other excision of pharynx and adjacent structures 
PJD Excision and block dissection of 
lymph nodes 
PJD51 Block dissection of cervical lymph nodes 
PJD71 Extended sparing excision of cervical lymph nodes 
PJD81 Excision of lymph nodes from upper part of neck 
ICD-10 codes for stomach cancer beginning with C16 
JDC Partial gastrectomy 
JDC00 Partial gastrectomy and gastroduodenostomy 
JDC10 Partial gastrectomy and gastrojejunostomy 
JDC11 Laparoscopic partial gastrectomy and gastrojejunostomy 
JDC20 Partial gastrectomy and Roux-en-Y reconstruction 
JDC40 Partial gastrectomy and oesophagogastrostomy 
JDC96 Partial gastrectomy with other reconstruction 
JDC97 Laparoscopic partial gastrectomy with other reconstruction 
JDD Total gastrectomy 
JDD00 Total gastrectomy and Roux-en-Y oesophagojejunostomy 
JDD96 Total gastrectomy with other reconstruction 
JDW Other operations on stomach 
and duodenum 
JDW98 Other transluminal endoscopic operation on stomach or 
duodenum 
JFA Local operations on intestine 
JFA65 Endoscopic insertion of ileum stent 
JFC Anastomosis of intestine 
JFC20 Other enterocolostomy 
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ICD-10 codes for pancreatic cancer beginning with C25 
JKD Biliodigestive anastomosis 
without excision 
JKD10 
Anastomosis of bile duct to duodenum 
  JKD20 
Anastomosis of bile duct to jejunum 
  JKD30 Extrahepatic anastomosis of right or left hepatic duct to 
jejunum 
JKE Transduodenal operations on 
bile duct or ampulla of Vater 
JKE02 Transduodenal endoscopic incision of common bile duct 
orifice 
  
JKE18 Endoscopic internal drainage of bile duct 
  
JKE25 Endoscopic external drainage of bile duct 
  
JKE32 Endoscopic dilatation of bile duct 
  
JKE98 Other transduodenal endoscopic operation on bile duct or 
ampulla of Vater 
JKW Other operations on biliary tract 
JKW98 Other transluminal endoscopic operation on biliary tract 
JLB Incision, drainage or dilatation 
of pancreas 
JLB12 Transduodenal endoscopic incision of pancreatic duct 
orifice 
  
JLB28 Endoscopic internal drainage of pancreatic duct 
  
JLB42 Transduodenal endoscopic dilatation of pancreatic duct 
JLC Excision of pancreas 
JLC10 Distal pancreatectomy 
  
JLC11 Laparoscopic distal pancreatectomy 
  
JLC30 Pancreatoduodenectomy 
  
JLC40 Total pancreatoduodenectomy 
  
JLC50 Atypical pancreatectomy 
JLW Other operations on pancreas 
JLW98 Other transluminal endoscopic operation on pancreas 
ICD-10 codes for lung and tracheal cancers beginning with C33-34 
GBC Resection and reconstruction of 
trachea 
GBC03 Resection of trachea 
  
GBC10 Resection and reconstruction of carina 
GDB Minor resections of lung 
GDB10 Wedge resection of lung 
  
GDB11 Thoracoscopic wedge resection of lung 
  
GDB20 Segmental resection of lung 
  
GDB21 Thoracoscopic segmental resection of lung 
  
GDB96 Other minor resection of lung 
GDC Lobectomy of lung 
GDC00 Lobectomy of lung 
  
GDC01 Thoracoscopic lobectomy of lung 
  
GDC10 Bilobectomy of lung 
  
GDC11 Thoracoscopic bilobectomy of lung 
  
GDC13 Extended lobectomy or bilobectomy of lung 
  
GDC20 Lobectomy of lung and sleeve resection of bronchus 
  
GDC23 Lobectomy and segment resection of lung 
GDD Pneumonectomy 
GDD00 Pneumonectomy 
  
GDD01 Thoracoscopic pneumonectomy 
  
GDD20 Extended pneumonectomy 
  
GDD23 Pneumonectomy and resection of carina 
  
GDD26 Pneumonectomy and resection of bronchus or bronchus 
and trachea 
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ICD-10 codes for melanoma beginning with C43 
CBB Excision or destruction of 
lesion of eyelid 
CBB30 Excision of lesion of eyelid 
CBB50 Excision of lesion of eyelid and reconstruction using graft 
or flap 
DAB DAB00 Excision of lesion of auricle 
DAB10 Partial excision of auricle 
ELB Excision of salivary gland ELB40 Partial parotidectomy 
ELB50 Total parotidectomy 
NDQ Amputations and related 
operations in wrist and hand 
NDQ20 Amputation of finger 
NHQ Amputations and related 
operations on ankle and foot 
NHQ40 Amputation of toe 
PJA Exploration of lymph nodes PJA12 Sentinel node biopsy 
PJD Excision and block dissection 
of lymph nodes 
PJD41 Excision of cervical lymph nodes 
PJD42 Excision of axillary lymph nodes 
PJD45 Excision of inguinal lymph nodes 
PJD51 Block dissection of cervical lymph nodes 
PJD52 Block dissection of axillary lymph nodes 
PJD54 Block dissection of iliac lymph nodes 
PJD55 Block dissection of inguinal lymph nodes 
PJD71 Extended sparing excision of cervical lymph nodes 
PJD81 Excision of lymph nodes from upper part of neck 
PJD99 Excision of other lymph nodes 
PXA Extracorporal circulation of 
different vascular sites 
PXA00 Extracorporal circulation of upper extremity using heart-
lung assist device 
PXA20 Extracorporal circulation of lower extremity using heart-
lung assist device 
QAE Excision and repair of lesion of 
skin of head and neck 
QAE10 Excision of other lesion extending through all layers of skin 
in head or neck 
QAE99 
QBE Excision and repair of lesion of 
skin of trunk 
QBE10 Excision of other lesion extending through all layers of skin 
of trunk 
QBE99 Other excision or repair of lesion of skin of trunk 
QCE Excision and repair of lesion of 
skin of upper limb 
QCE10 Excision of other lesion extending through all layers of skin 
in upper limb 
QCE99 Other excision or repair of lesion of skin of upper limb 
QDE Excision and repair of lesion of 
skin of lower limb 
QDE10 Excision of other lesion extending through all layers of skin 
in lower limb 
QDE99 Other excision or repair of lesion of skin of lower limb 
QXE Excision and repair of lesion of 
skin 
QXE10 Excision of other lesion extending through all layers of skin 
in uspecified region 
QXE99 Other excision or repair of unspecified region of skin 
4 Follow-up of access to cancer care 
 
National Institute for Health and Wel-
fare (THL) – Directions 4/2017 
32 
Follow-up of access to 
 cancer care  
 
 
 
ICD-10 codes for endometrial cancer beginning with C54 
LCD Total excision of uterus 
LCD01 Total laparoscopic hysterectomy 
  
LCD00 Hysterectomy 
  
LCD04 Laparoscopic hysterectomy 
  
LCD10 Vaginal hysterectomy 
  
LCD11 Laparoscopically assisted vaginal hysterectomy 
  
LCD97 Other laparoscopic hysterectomy 
PJD Excision and block dissection of 
lymph nodes 
PJD53 Block dissection of aortic lymph nodes 
  
PJD54 Block dissection of iliac lymph nodes 
  
PJD63 Laparoscopic dissection of aortic lymph nodes 
  
PJD64 Laparoscopic dissection of iliac lymph nodes 
ICD-10 codes for ovarian cancer beginning with C56, C57.0-8 
LAF Excision of ovary and Fallopian 
tube 
LAF00 Unilateral salpingo-oophorectomy 
  
LAF10 Bilateral salpingo-oophorectomy 
  
LAF11 Laparoscopic bilateral salpingo-oophorectomy 
  
LAF16 
Excision of uterus, adnexes and lymph nodes for treat-
ment of ovarian cancer 
  
LAF17 Laparoscopic excision of uterus, adnexes and lymph 
nodes for treatment of ovarian cancer 
LAE Total excision of ovary 
LAE10 Unilateral oophorectomy 
  
LAE11 Unilateral laparoscopic oophorectomy 
  
LAE20 Bilateral oophorectomy 
  
LAE21 Bilateral laparoscopic oophorectomy 
JAH Opening of peritoneal cavity 
JAH00 Laparotomy 
  
JAH01 Laparoscopy 
JAQ Extensive excision of peritone-
um and related procedures 
JAQ00 Extensive excision of peritoneum 
PJD Excision and block dissection of 
lymph nodes 
PJD53 Block dissection of aortic lymph nodes 
  
PJD54 Block dissection of iliac lymph nodes 
  
PJD63 Laparoscopic dissection of aortic lymph nodes 
  
PJD64 Laparoscopic dissection of iliac lymph nodes 
ICD-10 codes for testicular cancer beginning with C62 
KFA Exploration and incision of 
scrotum and scrotal organs 
KFA00 Exploration of testis 
KFC Total excision of testis and 
epididymis 
KFC00 Unilateral orchiectomy 
KFD Partial excision of scrotal 
organs 
KFD00 Partial excision of testis 
PJA Exploration of lymph nodes 
PJA10 Exploration of lymph nodes 
PJD Excision and block dissection 
of lymph nodes 
PJD53 Block dissection of aortic lymph nodes 
  
PJD54 Block dissection of iliac lymph nodes 
  
PJD63 Laparoscopic dissection of aortic lymph nodes 
  
PJD64 Laparoscopic dissection of iliac lymph nodes 
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ICD-10 codes for kidney cancer beginning with C64 
KAC Total excision of kidney 
KAC10 Total nephrectomy with capsule 
KAC11 Total nephrectomy with capsule, transcutaneous 
KAD Partial excision or destruction 
of tumour of kidney and pelvis 
of kidney 
KAD00 Partial nephrectomy 
KAD01 Percutaneous endoscopic partial nephrectomy 
KAD10 Heminephrectomy 
KAD60 Percutaneous destruction of lesion of renal parenchyma 
ICD-10 codes for bladder and urinary tract cancers beginning with C65-68 
KAC Total excision of kidney 
KAC20 Nephroureterectomy 
KAC21 Percutaneous endoscopic nephroureterectomy 
KBD Partial excision of ureter and 
destruction of tumour of ureter 
KBD00 Partial excision of ureter 
KBD20 Destruction of tumour of ureter 
KBD21 Percutaneous endoscopic destruction of tumour of ureter 
KBD22 Retrograde ureteroscopic destruction of tumour of ureter 
KCC Total excision of bladder 
KCC00 Cystectomy 
KCC10 Cystoprostatectomy 
KCC20 Cystoprostatourethrectomy 
KCC30 Cystectomy with excision of female internal genital organs 
KCC96 Other cystectomy 
KCD Partial excision of bladder and 
destruction of tumour of bladder 
KCD02 Transurethral resection of bladder 
KCD05 
Removal of lesion from urinary bladder during cystoscopy 
using photodynamic diagnostics (PDD) 
KCD10 Partial cystectomy 
KCD30 Destruction of tumour of bladder 
KCD32 Cystoscopic destruction of tumour of bladder 
KDC 
KDC00 Urethrectomy 
KDD 
KDD00 Partial excision of urethra 
KDD30 Destruction of tumour of urethra 
ICD-10 codes for brain and central nervous system cancer beginning with C70-72, C75.1-3 
AAB Excision and destruction of 
intracranial lesion 
AAB00 Extirpation of intracranial lesion 
AAB10 Partial excision of intracranial lesion 
ABB Operations for lesions of 
spinal cord and nerve roots 
ABB00 Excision of lesion of spinal canal 
ABB10 Resection of lesion of spinal canal 
ICD-10 codes for lymphomas beginning with C81-85 
JMA Partial splenectomy 
JMA10 Transabdominal total splenectomy 
JMA11 Laparoscopic total splenectomy 
JMA20 Transthoracic total splenectomy 
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4.5.3 Instructions for recording chemotherapies 
 
General chemotherapy recording principles 
 
Planning of intervention or health care consultation WZC00 is recorded for appointments with various 
specialists for the purpose of planning chemotherapy 
 in connection with the first planning visit, when treatment plans change (e.g. planning of the sec-
ond course of treatment or change of chemotherapy for progressive cancer), when making a deci-
sion to adopt active surveillance as the line of treatment, and when starting palliative treatment. 
Recording chemotherapy procedure codes 
 Individual oral and injected chemotherapies are recorded as procedures carried out during the 
doctor’s appointment at which the treatment is planned. The procedures to be recorded are ‘Plan-
ning of intervention or health care consultation’ WZC00, and the chemotherapy prescribed (codes 
listed in tables 8-10).   
o Oral and injected chemotherapies are recorded as administered treatment procedures at any 
first treatment appointments with a nurse, and at each appointment with a nurse or doctor 
during which the chemotherapy is reviewed. 
o Injected therapies are recorded as administered treatment procedures after the injection. 
 For infusion therapies, the doctor determines the procedure code during the treatment planning 
appointment.  The procedure recorded for the planning appointment is ‘Planning of intervention or 
health care consultation’ WZC00. The nurse records the administration of chemotherapy during 
the planning appointment in accordance with the doctor’s instructions.  
Chemotherapies involving combinations of pharmaceutical substance groups are recorded with sep-
arate procedure codes. These procedure codes are recorded for all treatment days during an inpatient stay, 
even if only one drug was administered at the time in question. If chemotherapy administered over the 
course of several days includes antibody therapy, the procedure code for antibody therapy is recorded for 
the day on which it was administered. The order in which procedure codes for chemotherapy are recorded 
is irrelevant to reporting related to access to care. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Examples of recording practices 
 
Intravenous adjuvant chemotherapy for colorectal cancer 
 The procedure code recorded in connection with the first appointment is WZC00, and infor-
mation on the the planned chemotherapy is entered in the text section. 
 The chemotherapy procedure code (e.g. WB113, CAPOX) is recorded for the days on which 
infusion therapy was given.   
 
Oral adjuvant chemotherapy for colorectal cancer 
 In connection with the first visit, procedure code WZC00 is recorded, as is the chemotherapy 
procedure code (e.g. WB103 capecitabin).  
 In connection with doctor’s or nurse’s appointments or telephone consultations in which the 
continuity of chemotherapy is discussed and/or a new treatment cycle is begun, the chemother-
apy procedure code is recorded (e.g. WB103 cabecitabin). 
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Neoadjuvant chemotherapy for HER-2 positive breast cancer 
 The procedure code recorded in connection with the first appointment is WZC00, and infor-
mation on the the planned chemotherapy is entered in the text section.
 Procedure codes (e.g. WB610 pertuzumab and trastuzumab combination therapy and WB121
docetaxel) are recorded for infusion administration days.
Neoadjuvant hormone therapy for prostate cancer before radiotherapy 
 The procedure code recorded in connection with the first appointment is WZC00, and the pro-
cedure code WB221 is recorded for the LHRH analogue neoadjuvant therapy.
 The procedure code WB221 is also recorded for appointments or telephone consultations dur-
ing which the continuity of chemotherapy is discussed, and after the completion of chemother-
apy.
Prostate cancer with bone metastases 
 The procedure code recorded in connection with the first appointment is WZC00, and the pro-
cedure code WD225 is recorded for the LHRH analogue treatment and procedure code WD305
for bone medication.
 Procedure codes WD225 and WD305 are also recorded for appointments or telephone consulta-
tions during which changes are made to the chemotherapy, and after the administration of each
course of chemotherapy.
Oral treatment of advanced kidney cancer 
 The procedure code recorded in connection with the first appointment is WZC00, and the pro-
cedure code WD505 is recorded for oral tyrosine kinase inhibitor therapy.
 The procedure code WD505 is also recorded in connection with a doctor’s or nurse’s appoint-
ments or telephone consultations, during which changes are made to the chemotherapy or a
new course of treatment is begun.
Intravenous treatment of advanced kidney cancer 
 The procedure code recorded in connection with the first appointment is ‘Treatment planning
or consultation’ WZC00, and information on the planned chemotherapy is entered in the text
section.
 The procedure code (e.g. WD325 nivolumab) is recorded for the days on which infusion thera-
py was given.
Adjuvant chemotherapy for testicular cancer 
 The procedure code recorded in connection with the first appointment is ‘Treatment planning
or consultation’ WZC00, and information on the planned chemotherapy is entered in the text
section.
 The chemotherapy procedure code (e.g. WB113 BEP) is recorded for each day on which infu-
sion therapy was given.
Chemotherapy for advanced cancer of the head and neck area 
 The procedure code recorded in connection with the first appointment is ‘Treatment planning
or consultation’ WZC00, and information on the planned chemotherapy is entered in the text
section.
 The chemotherapy procedure code (e.g. WD125 cisplatine and fluorouracil) is recorded for
each day on which infusion therapy was given, and, if required, the procedure code for the ad-
ministration of an antibody (e.g. WD405 cetuximab).
4 Follow-up of access to cancer care 
 
National Institute for Health and Wel-
fare (THL) – Directions 4/2017 
36 
Follow-up of access to 
 cancer care  
 
 
Treatment of the primary and local tumour 
 
The drugs to be used are recorded with codes listed in table 8. Adjuvant therapy is additional treatment, 
such as chemotherapy given in addition to cancer surgery, with the objective of destroying any micrometas-
tases. Neoadjuvant therapy for cancer is given before an operation. 
 
When treatment of high risk local prostate cancer is initiated with hormonal therapy, and radiotherapy is 
not planned because of patient’s condition or other reasons, the procedure codes for adjuvant therapy shall 
be used 
 WB203 Simple adjuvant hormone therapy of malignancy, bicalutamid 
 WB223 Demanding adjuvant hormone therapy of malignancy, LHRH agonists 
 
Table 8. Procedure odes used in the drug treatment of a primary/local tumour 
Adjuvant therapy 
Code Procedure Drugs used 
WB103 
Simple adjuvant cytostatic therapy 
Single-agent chemotherapy, e.g. docetaxel  
WB113 
Multiple adjuvant cytostatic therapy 
Combination chemotherapy, e.g. CEF, 
XELOX 
WB203 
Simple adjuvant hormone therapy of malignancy 
Aromatase inhibitors, tamoxifen 
WB223 Demanding adjuvant hormone therapy of malignancy LHRH analogues 
WB401 Simple antibody therapy of primary tumour Antibody therapy with a single agent, such as 
trastuzumab 
WB402 Demanding antibody therapy of primary tumour Combination antibody therapy, such as 
pertuzumab & trastuzumab 
WB303 Simple adjuvant therapy of malignancy with biomodifiers Interferon 
WB323 Demanding adjuvant therapy of malignancy with biomodifi-
ers 
Ipilimumab, nivolumab, pembrolizumab 
WB501 Simple enzyme inhibitor or similar therapy of primary tu-
mour 
Imatinib  
Neoadjuvant therapy  
WB121 
 
Demanding neoadjuvant  cytostatic therapy Preoperative chemotherapy 
WB201 
Simple neoadjuvant hormone therapy of malignancy 
Aromatase inhibitors 
WB221 
Demanding neoadjuvant hormone therapy of malignancy 
LHRH analogues 
WB321 Multiple adjuvant therapy of malignancy with biomodifiers 
 
WB600* Neoadjuvant therapy of primary tumour with antibod-
ies                         
 
WB610* 
Demanding neoadjuvant therapy of tumour with antibodies  
* Classification will be supplemented; this code will be available for use in 2017 
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Treatment of a locally recurrent tumour  
The drugs to be used are recorded with codes listed in table 9. No distinction is required between adjuvant 
and neoadjuvant therapies in the treatment of recurrent tumours. 
Table 9. Procedure codes used in the chemotherapy of a locally recurrent  tumour 
Adjuvant and neoadjuvant therapies 
Code Procedure Drugs used 
WC105 
Simple cytostatic therapy of local tumor recidive Single-agent chemotherapy, e.g. docetaxel, 
WC125 
Demanding cytostatic therapy of local tumor recidive Combination chemotherapy, e.g. CEF, 
CAPOX  
WC205 
Simple therapy of local tumor recidive with hormone Aromatase inhibitors, tamoxifen 
WC225 
Demanding therapy of local tumor recidive with hormone LHRH analogues 
WC305 
Simple therapy of local tumor recidive with biomodifiers Interferon 
WC325 
Demanding therapy of local tumor recidive with biomodifiers Ipilimumab, nivolumab, pembrolizumab 
WC401 
Simple antibody therapy of local recurrence of tu-
mour     
Single-agent antibody therapy, e.g. 
trastuzumab 
WC402 
Demanding antibody therapy of local recurrence of tu-
mour     
Combination antibody therapy, such as per-
tuzumab & trastuzumab 
WC501 
Simple enzyme inhibitor or similar therapy of local recur-
rence of tumour 
Tyrosine kinase inhibitor, e.g. sunitinib, lapa-
tinib 
4 Follow-up of access to cancer care 
 
National Institute for Health and Wel-
fare (THL) – Directions 4/2017 
38 
Follow-up of access to 
 cancer care  
 
 
Chemotherapy for metastatic cancer 
  
Drugs used for the treatment of metastatic cancer are recorded with codes listed in table 10. Treatment 
given for lymphomas is recorded using the procedure codes for metastatic cancer. 
 
Other combination therapies are recorded using separate codes, such as:  
 Bevacizumab and CAPOX: WD125 and WD405 
 Pertuzumab, trastuzumab and docetaxel WD105 and WD415 
 
Table 10. Procedure codes used in the drug treatment of metastatic cancer 
Drug treatment of metastatic cancer 
Code Procedure Drugs used 
WD105 
 
Cystostatic therapy of methastized malignancy Single-agent chemotherapy (oral and inject-
ed), e.g. docetaxel, capecitabine 
WD125 
 
Demanding cystostatic therapy of methastized malignancy Combination chemotherapy, e.g. CEF, 
CAPOX and oral combination chemotherapy 
such as capecitabine & temozolimide 
WD205 
 
Therapy of methastized malignancy with hormones E.g. aromatase inhibitors, tamoxifen, bicalu-
tamide, abiraterone, enzalutamide 
WD225 
 
Demanding therapy of methastized malignancy with hor-
mones 
E.g. LHRH analogues, fulvestrant 
WD305 
 
 
Simple therapy of methastized malignancy with biomodifiers E.g. interferon, zoledronic acid and deno-
sumab 
WD325 
 
Demanding therapy of methastized malignancy with bio-
modifiers 
Immunological drugs such as ipilimumab, 
nivolumab, pembrolizumab 
WD405 
 
Simple antiboidy therapy of methastized malignancy Single-agent antibody therapy, e.g. 
Trastuzumab, rituximab, bevacizumab 
WD415 
 
 
Demanding antibody therapy of methastized malignancy Combination antibody therapy and antibody 
therapy in combination with chemotherapy, 
such as pertuzumab & trastuzumab, 
trastuzumab emtancine 
WD505 
 
Simple enzyme inhibitor or similar therapy of methastized 
malignancy 
Tyrosine kinase inhibitor as a single agent, 
e.g. sunitinib, erlotinib, lapatinib 
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4.5.4 Instructions for recording radiotherapy 
General radiotherapy recording principles 
Planning of intervention or health care consultation WZC00 is recorded for doctor’s appointments for 
the purpose of planning radiotherapy. Descriptive procedure code(s), or Y code(s), are recorded according 
to the instructions given by each centre. 
The doctor determines the radiotherapy procedure code, or the code describing the objective or stage of 
the treatment, or the stage of the cancer (table 11), in connection with a visit to assess the treatment or to 
prescribe radiotherapy. These include procedure codes beginning with WF0, HA0, WA0 and XX7, and also 
codes AX099 and QX099. 
 If several areas are treated with different dose plans during the same treatment cycle, the corre-
sponding number of procedure codes must be recorded. Procedure codes are recorded in connec-
tion with each radiotherapy visit.
The radiotherapy planning work code is XX3DW (Time consuming IT work) and it is recorded on the 
first day of each course of radiotherapy treatment. Code XX3DW will be recorded twice if two separate 
areas are treated during the same course of treatment. If an entirely new dose plan is prepared during one 
inpatient stay, code XX3DW will be recorded when treatment with the new plan begins.  
Procedure codes describing the radiation technology used (prefix ZX0) should be recorded according to 
the instructions provided by each centre.  
 The procedure code for stereotactic radiotherapy is ZX050 regardless of the area being treated or
the stage of treatment (curative/palliative). Please note that ZX is a so-called additional code and
always requires a main procedure code. For instance, the main code for the treatment of metastasis
is WF049.
 Chemoradiotherapy procedure code is ZX095.
The procedure codes for cancer drugs used in chemoradiotherapy are those listed for adjuvant thera-
pies: WB103, WB113 WB223 and WB401 (table 11). 
 The doctor determines the procedure code for the cancer drug and is recorded in the same way as
any other chemotherapy (see section 4.5.3).
Examples of recording practices 
Breast cancer: Radiotherapy for a patient undergone partial mastectomy 
 The procedure code recorded in connection with the first appointment is WZC00. During this
visit, or when prescribing radiotherapy, information regarding the planned radiotherapy is en-
tered in the text section.
 The Y code describing the visit involving the planning of the radiotherapy is recorded in ac-
cordance with the centre’s own practices.
 The radiotherapy planning work code XX3DW is recorded during the first treatment session.
 The radiotherapy procedure code HA003 is recorded for each radiotherapy treatment visit.
 The ZX technology codes are recorded according to the centre’s own practices.
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Rectal cancer: Preoperative chemoradiotherapy  
 The procedure code recorded in connection with the first appointment is WZC00, and, when 
required, procedure code WB103 for chemotherapy tablet (e.g. capecitabine). During this visit, 
or when prescribing radiotherapy, information regarding the planned radiotherapy is entered in 
the text section. 
 The Y code describing the visit involving the planning of the radiotherapy is recorded in ac-
cordance with the centre’s own practices. 
 The radiotherapy planning work code XX3DW is recorded during the first treatment session. 
 The chemoradiotherapy code ZX095 is recorded according to the centre’s own practices. 
 The radiotherapy code WF001 is recorded for each radiotherapy treatment visit. 
 The ZX technology codes are recorded according to the centre’s own practices. 
 
Head and neck cancers: A course of definitive chemoradiotherapy   
 The procedure code recorded in connection with the first appointment is ‘Planning of interven-
tion or health care consultation’ WZC00. During this visit, or when prescribing radiotherapy, 
information regarding the planned radio or chemotherapy is entered in the text section. 
 The Y code describing the visit involving the planning of the radiotherapy is recorded in ac-
cordance with the centre’s own practices.  
 The radiotherapy planning work code XX3DW is recorded during the first treatment session. 
 The Y code and XX3DW will be recorded again if the preparation of a new description and a 
new plan is required during the course of radiotherapy treatment. 
 The radiotherapy procedure code WF002 is recorded for each radiotherapy treatment visit. 
 The chemoradiotherapy code ZX095 is recorded according to the centre’s own practices. 
 The ZX technology codes are recorded according to the centre’s own practices. 
 The unit administering intravenous chemotherapy records WB103 (e.g. cisplatine) every time 
the drug is administered. 
 
Prostate cancer: External radiotherapy combined with hormone therapy 
 The procedure code recorded in connection with the first appointment is WZC00. During 
this visit, or when prescribing radiotherapy, information regarding the planned radiotherapy 
is entered in the text section. Hormone therapy is recorded as a procedure if it is started or 
discussed during this appointment.  
 The Y code describing the visit involving the planning of the radiotherapy is recorded in ac-
cordance with the centre’s own practices. 
 The radiotherapy planning procedure code XX3DW is recorded during the first treatment 
session. 
 The radiotherapy procedure code WF002 is recorded for each radiotherapy treatment visit.  
 The ZX technology codes are recorded according to the centre’s own practices. 
 Procedure code WB223 is recorded on the day a hormone injection is administered. 
 
Palliative radiotherapy for a bone metastasis of lung cancer and the primary tumour, two separate 
treatment areas. 
 The procedure code recorded in connection with the first appointment  is WZC00. During 
this visit, or when prescribing radiotherapy, information regarding the planned radiotherapy 
is entered in the text section. 
 The Y code describing the visit involving the planning of the radiotherapy is recorded in ac-
cordance with the centre’s own practices. 
 The radiotherapy planning procedure code XX3DW x 2 is recorded during the first treat-
ment session. 
 Radiotherapy procedure codes WF004 and WF049 are recorded for all radiotherapy visits. 
 The ZX technology codes are recorded according to the centre’s own practices.  
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Table 11. Procedure odes used in the radiotherapy of metastatic cancer 
Primary tumour/local 
Code Procedure More detailed description, examples 
WF001 Preoperative radiotherapy 
E.g. Preoperative treatment of rectal cancer
WF002 Radical radiotherapy 
Definitive treatment in which radiotherapy is provided as the only 
curative treatment. Examples: 
- Head and neck cancers
- All brain tumours (also if radiotherapy is the second-line
treatment)
- Prostate cancer (including treatment given after active sur-
veillance)
- High-dose treatment of acoustic neuroma, meningioma and
similar.
WF003 Adjuvant radiotherapy Treatment provided in addition to or as part of other curative 
treatment. Examples: 
- Postoperative and post-cytostatic therapies treatments (for
lymphomas)
- So-called prophylactic brain radiotherapy for lung cancer (to
treat potential micrometastasis)
HA003 Radiotherapy after partial ablation of 
mammary gland 
Breast and the necessary lymph nodes 
As an adjuvant therapy to surgery  
HA013 Radiotherapy after total ablation of 
mammary gland 
Chest and the necessary lymph nodes 
As an adjuvant therapy to surgery 
Local recurrence of a tumour after radical treatment 
WF029 Radiotherapy of local residive tumor - Radical dose treatment of a recurrent tumour
- All repeat/additional radiotherapies, such as salvage treat-
ment for prostate cancer
Palliative treatment of a local tumour 
WF004 Palliative radiotherapy - Local treatment to alleviate the symptoms of the primary
disease
- Treatment to alleviate the symptoms of a locally recurrent or
progressive disease
- E.g.  lung cancer
Palliative treatment of advanced cancer 
WF049  Radiotherapy of metastasis Regardless of the number or location of metastases or areas to 
be treated 
- The treated area may also cover the primary tumour
Body radiotherapy 
WA010 
Adjuvant whole body radiotherapy 
WA029 
Half body radiotherapy 
QX099 
Whole skin radiotherapy 
Prophylactic radiotherapy 
WF090 Profylactic radiotherapy E.g. Radiotherapy for mammary glands before the start of
antiandrogen treatment 
Radiotherapy for the central nervous system 
AX099 Radiotherapy of whole central nervous sys-
tem 
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Other radiotherapy  
WF099 Other radiotherapy E.g. Low-dose therapy for lymph nodes 
Chemoradiotherapy and drug codes 
ZX095 Combined chemoradiotherapy  
WB103 Simple adjuvant cytostatic therapy 
E.g. capecitabine, cisplatine 
WB113 Multiple adjuvant cytostatic therapy 
E.g. Combination therapy with cisplatine and fluorouracil  
WB223 Demanding adjuvant hormone therapy of 
malignancy 
E.g. LHRH analogue 
(NB. Start of neoadjuvant therapy WB221) 
WB401 Simple antibody therapy of primary tumour E.g. cetuximab 
Radioisotope therapies 
XX7AT Radiation therapy with Radium-223  
XX7CT Radioiodine therapy of thydoid tissue  
XX7FT Radioyttrium therapy with connected antibody  
XX7GT Selective internal radio therapy (SIRT) with 
Yttrium 
 
XX7JT Somatostatin isotope ablative therapy  
XX7KT Radiosamarium therapy  
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4.5.5 Instructions for recording other procedures 
Other procedures associated with cancer therapies, such as stem cell transplantation and various local 
treatments of tumours or abnormal tissue, such as laser therapies. 
Table 12. Codes for other procedures used in the treatment of cancer 
Stem cell transplant 
Code Procedure 
WW300 Transfer of autologic stem cells 
WW302 Allogenic transfer of stem cells from relative 
WW304 Transfer of stem cells from registered domestic 
donator 
WW306 Transfer of stem cells from foreign registered 
donator 
WW310 Transfer of stem cells from cord blood 
Local treatment of tumour or abnormal tissue 
GBA25 Endoscopic electrocoagulation of lesion of 
trachea 
GBA28 Endoscopic laser therapy of lesion of trachea 
JJA43 Destruction of lesion of liver 
JJA44 Laparoscopic destruction of lesion of liver 
XX6DT Embolization of other tumour with radiological 
guidance 
XX6LT Coagulation of tumour with radiological guid-
ance 
TJJ10 Percutaneous destruction of lesion of liver 
JN4NT Coagulation of tumour in trunk with radiological 
guidance 
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5 Submitting the data 
Data is submitted as instructed in the Hilmo guide, because the data is collected for the Hilmo register. As 
of the beginning of 2017, this data can be submitted to the National Institute for Health and Welfare (THL) 
once a month. 
6 Reporting 
Information on the actual waiting times of patients diagnosed with cancer will be available on THL’s web-
site as soon as the quality of the data reaches an acceptable level.  
Reports will be updated monthly as soon as hospitals are able to submit monthly data to the Hilmo register. 
The waiting period for access to care will be determined on the basis of actual treatment periods, in which 
case data regarding the arrival of the cancer patient’s referral, doctor’s appointment and placement on a 
waiting list will be retrieved retroactively. 
For all types of cancers included in the follow-up system, data will be grouped by the patient’s residence 
and the service provider. 
The indicators used to describe the general situation (from arrival of referral to the first appointment with a 
doctor, and from placement on the waiting list to the first treatment) are as follows: 
 Less than 2 weeks
 2 – 4 weeks
 More than 4 but no more than 6 weeks
 More than 6 but no more than 8 weeks
 More than 8 but no more than 12 weeks
It should be noted that these times are not recommendations; they are only provided for purposes of com-
parison.  
Instead, the times referred to in this guide regarding the treatment of breast, prostate and colorectal cancers 
are recommended maximum times (figures 2-5 on pages 18-19) within which treatment should be given.  
Compliance with recommendations can be assessed on the basis of actual waiting times before access to 
care, and the recommendations can then be changed and supplemented as necessary. 
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